Loading organizations...
The Swiss Helvetia Fund, Inc., now Total Return Securities Fund, is a non-diversified, closed-end investment company. It exclusively invests in equity and equity-linked securities of Swiss companies, offering direct market exposure. An active management strategy guides portfolio construction for long-term capital appreciation.
Established on October 24, 1986, The Swiss Helvetia Fund originated as a U.S.-domiciled vehicle for accessing Swiss equity. Its founding insight identified a need for a structured product, enabling investors to participate directly in Swiss corporate growth and their stable economy.
The fund serves investors seeking specialized exposure to Swiss companies via a professionally managed portfolio. Clientele includes individuals and institutions pursuing diversification and long-term growth in an international market. The vision focuses on consistently delivering capital appreciation by identifying value within the Swiss equity and equity-linked securities.
Swiss Helvetia Fund has 1 tracked investment across 1 company. The latest tracked deal is $30.0M Series C in Synosia Therapeutics in October 2010.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2010 | Synosia Therapeutics | $30.0M Series C | Greg Duncan | RED Tree Venture Capital, 5AM Ventures, Aravis, Investor Growth Capital, Novo Holdings, Versant Ventures |